The goal of this clinical trial is to learn if a virtually monitored, home-based prehabilitation program is feasible and acceptable for adults undergoing major elective surgery. The main questions it aims to answer are:
1. Can researchers successfully recruit and retain participants across multiple sites?
2. Will participants adhere to the prehabilitation program at a high enough rate to justify a larger trial?
Researchers will compare the prehabilitation program to standard preoperative care to see if the intervention is feasible to implement and whether it may help reduce postoperative complications.
Participants will:
* Be randomly assigned to receive either the prehabilitation program or usual care
* Complete questionnaires and physical assessments before and after the intervention
* (For those in the intervention group) Receive exercise, nutrition, and mindfulness guidance, protein supplements, and use the CloudDX virtual care platform to support their activities

Start Date01 Jun 2026

Sponsor / Collaborator

Queen's University

[+4]

ACTRN12626000229370

/ Not yet recruitingPhase 4IIT

Sphenopalatine Nerve Ganglion Block for Acute Benign Headaches in the Emergency Department: A Pilot Randomized Controlled Trial

Start Date01 May 2026

Sponsor / Collaborator

Ottawa Hospital Research Institute

NCT07491055

/ Not yet recruitingNot ApplicableIIT

Evaluation of Wide-Angle Tomosynthesis and AI in Diagnostic Mammography at The Ottawa Hospital

Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women globally. Timely and accurate detection is crucial for improving prognosis and survival outcomes. While digital mammography has long served as the gold standard for screening, it is limited by overlapping tissue structures, particularly in women with dense breasts, which can obscure malignancies or create false positives.
To address these limitations, digital breast tomosynthesis (DBT), especially wide-angle DBT, has been developed to offer three-dimensional imaging and reduce tissue overlap. Siemens' MAMMOMAT B.brilliant system, which incorporates wide-angle DBT, enhances spatial resolution and improves lesion conspicuity. This technology may offer significant benefits in diagnostic populations, where accuracy and confidence in imaging interpretation are crucial.
In parallel, artificial intelligence (AI) tools such as the Transpara system have been introduced to further improve mammographic interpretation. Previously the evaluation of Transpara in a sample of 310 Japanese women and found that while human readers outperformed AI in overall diagnostic performance, the system showed promising sensitivity levels, highlighting the potential of AI as a decision-support tool rather than a standalone reader.
More robust evidence is provided by the Mammography Screening with Artificial Intelligence (MASAI) trial, which assessed AI-supported screen reading in a controlled study of over 80,000 women. The trial found that AI-supported reading led to a comparable cancer detection rate as standard double reading (6.1 vs. 5.1 per 1000 participants) but reduced reading workload by 44.3% without increasing false positives or recall rates. A related analysis by the same team emphasized the capability of AI to triage exams effectively and highlighted that AI-flagged "extra high risk" mammograms accounted for a substantial portion (over 55%) of all screen-detected cancers, with a high positive predictive value.
Despite these encouraging findings, most studies have been limited to screening-based settings. There remains a lack of prospective evidence on the real-world diagnostic application of wide-angle DBT and AI in populations at higher risk, such as symptomatic patients or those recalled from screening. This represents a critical knowledge gap, especially given increasing concerns about radiologist workload and diagnostic delays.
The purpose of this prospective observational study is to evaluate the integration and diagnostic value of wide-angle tomosynthesis and AI (Transpara) in a clinical diagnostic setting. Specifically, it aims to assess their influence on radiologist confidence, diagnostic accuracy and the need for supplementary imaging. By addressing these questions, the study seeks to inform future implementation strategies that balance accuracy, efficiency, and clinical utility.

Start Date01 Apr 2026

Sponsor / Collaborator

Ottawa Hospital Research Institute

[+1]

100 Clinical Results associated with Ottawa Hospital Research Institute

0 Patents (Medical) associated with Ottawa Hospital Research Institute

6,657

Literatures (Medical) associated with Ottawa Hospital Research Institute

31 Dec 2026·Human Vaccines & Immunotherapeutics

Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study

Article

Author: Lam, Godfrey ; McHenry, Mary ; Barber, Colin ; Castellucci, Lana A. ; Rosenfield, Lana ; Belga, Sara ; Deeks, Shelley ; Rex, Greg ; Sadarangani, Manish ; Cameron, Scott B. ; Roches, Anne Des ; Constantinescu, Cora ; Zaborniak, Karver ; Bosonea, Ana ; Viel-Theriault, Isabelle ; Cowan, Juthaporn ; Pham-Huy, Anne ; Finlay, Jane ; McConnell, Athena ; Chew, Jo Lin ; Vaudry, Wendy ; Lacuesta, Gina ; Quach, Caroline ; Abdurrahman, Zainab ; McNeil, Shelly ; Halperin, Scott ; Morris, Shaun K. ; Mah, Allison ; De Serres, Gaston ; Wilson, Sarah ; Burton, Catherine ; Pernica, Jeffrey M. ; Naus, Monika ; Hildebrand, Kyla ; Chapdelaine, Hugo ; Grant, Ian ; Pourshahnazari, Persia ; Salvadori, Marina ; Gantt, Soren ; Buchan, C. Arianne ; Falcone, Emilia ; Piche-Renaud, Pierre-Philippe ; Rubin, Tamar ; Kalicinsky, Chrystyna ; Kanani, Amin ; Suresh, Sneha ; Top, Karina A. ; Morris, Shaun ; Shivakumar, Sundeep ; Drolet, Jean-Philippe ; Blaquiere, Martin ; Upton, Julia ; Mak, Raymond ; Betschel, Stephen ; Comeau, Jeannette ; Salvo, Grazia ; Simons, Elinor ; Sturtevant, Doris ; Cook, Victoria ; Wright, Alissa ; Vostretsova, Kateryna ; Song, Christine ; Gagnon, Remi ; Carignan, Alex ; Smolinski, Michael ; Fitzpatrick, Tiffany

Data on safety of revaccination after a hematologic adverse event following immunization (AEFI) with COVID-19 vaccines are limited. This study characterized hematologic AEFIs in patients assessed by Canadian Special Immunization Clinic (SIC) network physicians from January 2021 to February 2023 and estimated recurrence rates of hematologic events after revaccination. Following clinical assessment of 475 individuals, revaccinated participants were followed for recurrence of AEFI. Thirty-eight cases (21 [55.3%] males and 17 [44.7%] females) with hematologic AEFIs and aged ≥12 were included in the analysis; 31/38 participants (81.6%) were 18 to 64 y old. Immune thrombocytopenia, deep vein thrombosis and pulmonary embolism were the most common diagnoses, accounting for 11 (28.9%), 9 (23.7%) and 9 (23.7%), cases. Two cases of thrombosis with thrombocytopenia syndrome (TTS) were reported after ChAdOx1. The vaccines associated with hematologic AEFIs were BNT162b2 (17, 44.7%), ChAdOx1 (11, 28.9%), and mRNA-1273 (10, 26.3%). Twenty-seven (71.1%) participants were revaccinated; 14 (51.9%) received the same vaccine product as their initial vaccine while 13 (48.1%) received a different product. There were no recurrences of the same AEFI reported after revaccination with an mRNA vaccine, including the two patients with TTS, suggesting that hematologic AEFI recurrences following COVID-19 vaccines are likely uncommon.

01 Sep 2026·JOURNAL OF AFFECTIVE DISORDERS

Evening chronotype is associated with affective temperaments, emotional dysregulation, and bipolar-spectrum features: An observational study in 1997 adults from a large community sample

Article

Author: Preti, Antonio ; Solmi, Marco ; Steardo, Luca ; Caiolo, Stefano ; Fornaro, Michele ; Sambataro, Fabio ; Sarzetto, Alessandro ; Boldrini, Tommaso ; Miola, Alessandro ; Pontoni, Giancarlo ; Nunez, Nicolas A ; Ercis, Mete

BACKGROUND:

Growing evidence supports an association between chronotype and mental health, with evening chronotype (ET) being associated with increased vulnerability to bipolar disorder (BD).

METHODS:

We conducted a cross-sectional survey of adults recruited between February and September 2022 from community COVID-19 points of care in Padua, Italy. Participants completed validated self-report measures assessing chronotype (rMEQ), affective temperaments (Brief-TEMPS-M), emotion regulation (DERS), and subthreshold bipolarity (MDQ and HCL-32-R2). Group differences across chronotypes were examined using ANOVA. Associations between chronotype and psychopathological traits were assessed using regression models adjusted for age and sex. Logistic regression was used to identify sociodemographic and lifestyle factors associated with ET.

RESULTS:

A total of 1997 participants (mean age = 31.4 ± 12.35 years; 66.3% female) were enrolled. Overall, 22.68% had ET, 22.33% morning chronotype (MT), and 54.98% neither chronotype (NT). Compared with other chronotypes, ET was associated with higher depressive, anxious, irritable, and cyclothymic temperament, greater emotional dysregulation, and increased bipolar-spectrum scores (all p < 0.001). In logistic regressions, obesity, student status, tobacco and drug use, and lack of religious belief increased the odds of ET, whereas older age, parenthood, living with other people, and good/excellent sleep quality decreased the odds. Cross-sectional design and regional sampling may limit generalizability.

CONCLUSIONS:

Our findings support an association between ET and greater emotional dysregulation, cyclothymic temperament, and bipolar-spectrum features, suggesting that circadian-related patterns may be linked to mood instability. Chronotype may serve as a marker of bipolar-spectrum traits. Longitudinal studies are warranted to clarify causality and evaluate its integration into existing prediction/assessment tools for BD at-risk.

01 Aug 2026·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Prevalence and outcomes of co-occurring psychiatric and neurological disorders: An atlas based on umbrella review of 81 meta-analyses

Review

Author: Steardo, Luca ; Miola, Alessandro ; Kishi, Taro ; Di Lorenzo, Chiara ; Fornaro, Michele ; Radua, Joaquim ; Solmi, Marco ; Stubbs, Brendon

Psychiatric and neurological disorders often co-occur, complicating their assessment, management, and outcomes. No umbrella review (UR) has summarized the meta-analytic evidence on the co-occurrence of psychiatric and neurological disorders and assessed its credibility. Meta-analytic systematic reviews of observational studies documenting the prevalence and outcomes associated with the co-occurrence of neurological and psychiatric disorders, indexed from inception through August 25, 2025, and meeting established diagnostic criteria, were included. Meta-analytic prevalence and association estimates were recalculated and graded based on quantitative criteria. The AMSTAR-2 assessed the quality of the meta-analyses, while several subgroup analyses and meta-regressions aimed to explain the heterogeneity. We included 81 meta-analyses (N=42,464,788, k=2,273), yielding 166 meta-analytic estimates. Based on pre-existing meta-analytic evidence, among 90 prevalence estimates, 45 (50%) met moderate/strong credibility criteria. Strong credibility emerged in bipolar disorder for comorbid migraine (34.8%,95%CI=25.54-44.69) and chronic pain (28.9%,95%CI=16.4-43.4), in epilepsy for ADHD (22.3%,95%CI=20.3-24.4), depression (23.1%,95%CI=20.6-28.3), autism (11.1%,95%CI=9.8-12.1), and PTSD (7.7%,95%CI=5.2-11.2), in myasthenia gravis for anxiety (33%,95%CI=25.0-42.0 children), in multiple sclerosis for anxiety (36%,95%CI=30.0-42.0) and depression (27.01%,95%CI=22.80-31.68), in neuropathic chronic pain for depression (37.5%,95%CI=28.7-47.1) and anxiety (33.8%,95%CI=28.5-39.6), in neuromyelitis optica for depression (40%,95%CI=32.0-49.0), in stroke for anxiety (29.3%,95%CI=24.8-33.8) and depression (31%,95%CI=24.0-38.0 children), in dementia for depression (25.01%,95%CI=22.1-28.4). Several additional disorders were comorbid in >5%with lower credibility. No outcomes reached strong credibility criteria. The present study provides an atlas of neurological and psychiatric multimorbidity across varying levels of credibility, reinforcing the need for an integrated, multidisciplinary approach to patient care and for more research on actionable risk/protective factors and outcomes.

News (Medical) associated with Ottawa Hospital Research Institute

26 May 2026

·www.globenewswire.com

Brain Cancer Canada Invests $50,000 in Promising Immunotherapy Breakthrough Targeting One of the Most Aggressive Brain Tumours

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award $50,000 to an exciting research project led by Dr Ian Lorimer and his team at Ottawa Hospital Research Institute (OHRI). The project titled “Improving glioblastoma immunotherapy by selectively blocking macrophage activity” explores a new way of possibly treating glioblastoma (GBM) and might soon pave the way for a clinical trial. There is a clear need for new glioblastoma therapies that are more effective than today’s options that still only offer patients limited hope when faced with their diagnosis. Modern immunotherapy-based approaches have led to improved outcomes in other cancers, but GBM remains largely resistant to these recent advancements. Dr. Lorimer’s work focuses on one way in which GBM cells avoid the immune system and render modern immunotherapy treatments ineffective. By tracking and analyzing immune cells in these tumours and studying the effects of a potential new drug that can change the immune response, this project might uncover a new tool that could unlock an immunotherapy approach to treat glioblastoma in the future. “Glioblastoma is currently an incurable disease with very limited treatment options. Therapies that induce the patient’s immune system to eradicate their cancer have been successful in other cancer types, but so far have not worked in glioblastoma. Our Brain Cancer Canada grant will test a novel immunotherapy approach, hopefully providing a new and effective treatment for glioblastoma patients,” says Dr. Lorimer. “A colleague of mine was recently diagnosed with glioblastoma and I experience a mixture of grief and frustration with this news. We can stop this disease, but it takes a team and fundraisers such as Brain Cancer Canada, the Andrea Villamere Memorial Golf Tournament and the JP Leclerc Memorial Golf Tournament are a critical and essential part of this team.” Since this project focuses on an approach not yet deeply explored for GBM and with early experiments suggesting the therapy could be a feasible option, BCC sees high value in exploring this new avenue which will generate the data needed to assess whether this can continue further with a clinical trial. By funding innovative work like this, and at the early stages in research, we can ensure new ideas are tested and build hope for a better future for anyone receiving a brain cancer diagnosis. This announcement represents one of six grants awarded during Brain Cancer Awareness Month (May), combined to invest $425,000 in promising Canadian Brain Cancer research. This research grant was made possible through community fundraising including the Andrea Villamere Memorial Golf Tournament and the JP Leclerc Memorial Golf Tournament. “Thank you to Brain Cancer Canada and the incredible doctors advancing research—your work brings light to families facing the unimaginable and hope for a better future,” says Julie Villamere, mother of Andrea Villamere, who passed away in October 2023 at the age of 27. “Brain Cancer Canada has provided amazing support and compassion as we continue to navigate grief. Sharing Andrea's journey has hopefully shown families they are not alone and can reach out for support anytime.” “Brain Cancer Canada offers a space and place to bring communities together to support a cause that unfortunately touches so many families' lives. Their ongoing commitments to ultimately finding a cure for such a devastating cancer such as GBM turn grief into purpose and hope into action by raising critical funds for life-changing research to happen. Knowing that every donation brings us closer to a future where families no longer have to face a diagnosis of GBM alone is why we host the JP Leclerc Memorial Golf Tournament. We are grateful to be able to raise funds so the incredible doctors, and researchers can conduct their important work to find a cure for GBM,” says Esther Seaman, whose late Husband, JP Leclerc, passed away from glioblastoma. Brain Cancer Canada is a national charity dedicated to improving the lives of those affected by primary malignant brain tumours by funding research, advocating for effective treatment options, and investing in neurosurgical technologies. Recognized by the country’s leading neurospecialists as Canada’s foremost mechanism for brain cancer research funding, the organization raises funds through community-driven initiatives, generous year-round donations, its annual Gala for Brain Cancer Research, and Golf For Brain Cancer Research, and the support of corporate donors aligned with its mission. As a fully volunteer-based organization, Brain Cancer Canada ensures that every dollar raised is maximized toward critical research investments. Since 2015, it has directed nearly $3 million to brain cancer research, supporting 31 projects across more than a dozen institutions, research centres, and hospitals nationwide. About Brain Cancer Canada As a fully volunteer-based organization, Brain Cancer Canada ensures that every dollar raised is maximized toward critical research investments. Since 2015, it has directed nearly $3 million to brain cancer research, supporting 31 projects across more than a dozen institutions, research centres, and hospitals nationwide. More Information For more details about this and other research initiatives supported by Brain Cancer Canada, please visit www.braincancercanada.ca or contact Scientific Advisory Chair and Board Director, Elvin de Araujo, PhD, at elvin@braincancercanada.ca Media Contact: angela@braincancercanada.ca 1-855-375-1381

Immunotherapy

21 Apr 2026

·www.biospace.com

Virica Biotech Introduces Viric.AI, an Active Learning Platform to Accelerate Biomanufacturing Optimization

Ottawa, Ontario--(News - April 21, 2026) - Virica Biotech ("Virica"), an Ottawa-based company focused on improving biomanufacturing through its Viral Sensitizers (VSE™) enhancer technology, today announced the launch of Viric.AI™, a proprietary active learning platform that accelerates the discovery of optimized biomanufacturing enhancers, as part of their service offering to clients. Developed in collaboration with Dr. Francesco Gentile's lab at the University of Ottawa's Faculty of Science, Viric.AI™ combines machine learning with iterative experimental feedback to accelerate the precise identification of biomanufacturing enhancers tailored to specific client processes. Expanding Virica's existing rapid screening HTV TM platform capabilities, Viric.AI™ helps guide experimental design and predict the most productive conditions earlier in development. The synergy between HTV TM and Viric.AI TM platforms ultimately helps reduce process development timelines, improve biomanufacturing yield, and support novel biomanufacturing enhancer discovery and optimization across a range of systems, including but not limited to viral vector manufacturing leveraging its existing VSE TM technology. Viric.AI™ is already being utilized by the Canadian Pandemic Preparedness Hub (CP2H), a research Hub co-led by the University of Ottawa and McMaster University, in partnership with the Ottawa Hospital. Viric.AI™ is being leveraged by CP2H to support the discovery of novel enhancers for adenovirus production. This work highlights the platform's dual-use potential to support both commercial biomanufacturing programs and broader public health and biodefense preparedness efforts. "Biomanufacturing processes are inherently complex, and optimization has traditionally been slow and resource-intensive," said Dr. Jean-Simon Diallo, CEO of Virica Biotech. "With Viric.AI™, we're enabling our partners to move faster and make better decisions earlier, whether they're working in viral vectors or other advanced biologics systems." "Canada's ability to respond to future health threats depends on accelerating innovation in biomanufacturing," said Ottawa Hospital Research Institute scientist John Bell, who co-directs CP2H with McMaster Professor Matthew Miller. "Platforms like Viric.AI™ demonstrate how advanced technologies can bolster Canada's health security and sovereignty and strengthen our broader life sciences ecosystem." Virica acknowledges the support of the Life Sciences Critical Technologies and Commercialization Centre of Excellence, established by Ontario Biosciences Innovation Organization (OBIO) and Mitacs, whose funding contributed to the development of Viric.AI™. About Virica Biotech Virica develops biomanufacturing enhancers with a major focus on improving the yield and quality of viral vectors used for cell & gene therapies and vaccines. Virica's commercially available Viral Sensitizer (VSE™) enhancers overcome production inefficiencies in cells used for biomanufacturing and allow therapeutic developers to upscale the manufacture of their products at much lower cost. Beyond supplying VSEs as commercial biomanufacturing reagents, Virica operates as rapid process development service partner. Virica's proprietary High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) process optimization, and analytical testing workflows enable therapeutic developers to rapidly pinpoint the optimal biomanufacturing conditions allowing their programs to scale faster and at a lower cost than traditional methods. Contacts For further information, please contact: Dr. Jean-Simon Diallo Email: communications@viricabiotech.com Website: To view the source version of this press release, please visit

18 Mar 2026

·www.criteriuminc.com

Oncology News from Leading Researchers – March 2026

Study finds that de-escalating bone-modifying therapy is safe and effective in Metastatic Breast Cancer At the European Society for Medical Oncology Congress meeting in October 2025, research demonstrating an effective approach for patients with breast cancer bone metastases was presented by Terry L. Ng, M.D., of the Ottawa Hospital Research Institute in Canada and Criterium’s Academic Breast Cancer Consortium (ABRCC). Learn more about the study results Identifying ways to empower ALK+ NSCLC patients in their decision making At the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, Thomas E. Stinchcombe, M.D., of Duke Cancer Institute and Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) presented an abstract detailing methods and tools to empower ALK+ NSCLC patients in their decision making. Learn about ways to empower ALK+ NSCLC patients in their decision making

100 Deals associated with Ottawa Hospital Research Institute

100 Translational Medicine associated with Ottawa Hospital Research Institute

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 15 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Allogeneic umbilical cord-derived human mesenchymal stromal cells(Ottawa Hospital Research Institute)	Bronchopulmonary Dysplasia More	Phase 2
CLIC-1901 ( CD19 )	Diffuse Large B-Cell Lymphoma More	Phase 1/2
GSKJ-4 ( KDM6A x KDM6B )	Leukemia More	Preclinical
Vesiculovirus with SARS-CoV2 Spike Protein ( SARS-CoV-2 S protein )	Respiratory Distress Syndrome, Acute More	Preclinical
Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)	Shock, Septic More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis